Open the filing on EDGARApyx Medical Corporation Reports Second Quarter 2026 Financial Results
- Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment
- Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026
- Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million
- Management to host a conference call today at 4:30 p.m. ET
CLEARWATER, FL - August 6, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.
Recent Financial and Operating Highlights:
- Reported total revenue of $13.9 million in the second quarter of 2026, compared with $11.4 million in the same period last year.
- Surgical Aesthetics revenue increased to $12.4 million in the second quarter of 2026, compared to $9.7 million in the second quarter of 2025, which was the result of sales of AYON, Renuvion generators internationally, and single-use handpieces worldwide.
- OEM revenue was approximately $1.5 million in the second quarter of 2026, representing a decrease of 12% from the same period last year.
- Net loss attributable to stockholders of $3.2 million in the second quarter of 2026, compared with a net loss attributable to stockholders of $3.8 million in the second quarter of 2025.
- Adjusted EBITDA loss was $0.7 million for the second quarter of 2026, compared with Adjusted EBITDA loss of $2.0 million for the second quarter of 2025.
- Received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction and commenced a limited commercial launch of the reusable power liposuction handpiece with targeted early adopters.
- Published retrospective clinical data demonstrating that Renuvion used in combination with liposuction was associated with significantly higher patient satisfaction, lower abdominoplasty and revision rates and comparable complication rates versus liposuction alone.
- Reported positive clinical data demonstrating significant improvements in cellulite appearance and skin laxity following a single-session combination treatment utilizing Avéli and Renuvion.
- Showcased Renuvion and the AYON Body Contouring System at Miami Swim Week through the Body by Apyx event, highlighting real patient transformations and increasing awareness among consumers and aesthetic providers.
“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year,” said Charlie Goodwin, President and Chief Executive Officer. “U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day. With the recent FDA clearance of AYON's power liposuction capability, we are executing a measured rollout with key surgeons ahead of a initial commercial shipments in June. Alongside the expanding body of clinical evidence supporting Renuvion, these milestones reinforce our confidence in the long-term growth opportunity for our business. ”
The following tables present revenue by reportable segment and geography:
| Three Months Ended | | | Six Months Ended | | |
|---|
| June 30, | | | June 30, | | |
|---|
| (In thousands) | 2026 | 2025 | $ Change | % Change | 2026 | 2025 | $ Change | % Change |
| Surgical Aesthetics | $12,386 | $9,670 | $2,716 | 28.1% | $23,120 | $17,557 | $5,563 | 31.7% |
| OEM | 1,498 | 1,703 | (205) | (12.0)% | 3,254 | 3,246 | 8 | 0.2% |
| Total | $13,884 | $11,373 | $2,511 | 22.1% | $26,374 | $20,803 | $5,571 | 26.8% |
| Three Months Ended | | | Six Months Ended | | |
|---|
| June 30, | | | June 30, | | |
|---|
| (In thousands) | 2026 | 2025 | $ Change | % Change | 2026 | 2025 | $ Change | % Change |
| Domestic | $9,408 | $7,776 | $1,632 | 21.0% | $17,520 | $14,519 | $3,001 | 20.7% |
| International | 4,476 | 3,597 | 879 | 24.4% | 8,854 | 6,284 | 2,570 | 40.9% |
| Total | $13,884 | $11,373 | $2,511 | 22.1% | $26,374 | $20,803 | $5,571 | 26.8% |
Second Quarter 2026 Results:
Total revenue for the three months ended June 30, 2026, increased 22% to $13.9 million, compared with $11.4 million in the prior year period. Surgical Aesthetics segment sales increased 28%, or $2.7 million, to approximately $12.4 million for the three months ended June 30, 2026, when compared with $9.7 million for the three months ended June 30, 2025. The Surgical Aesthetics sales increase was driven by sales of AYON, which commenced with the commercial launch in the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces domestically. These increases were partially offset by decreases in domestic sales of standalone generators. OEM segment sales decreased 12%, or $0.2 million, to approximately $1.5 million for the three months ended June 30, 2026 when compared with $1.7 million for the three months ended June 30, 2025. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on Surgical Aesthetics, the Company expects that OEM segment revenue will decrease for the year and that this trend will continue over time.
Gross profit for the three months ended June 30, 2026, increased 25% to $8.9 million, compared with $7.1 million for the same period in the prior year. Gross margin for the three months ended June 30, 2026, was 63.9%, compared to 62.3% for the same period in 2025. The increase in gross margin for the three months ended June 30, 2026 from the prior year period is primarily attributable to mix between the Company’s segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within the OEM segment. This was partially offset by tariffs that began effecting the Company in the second half of 2025.
Operating expenses increased to $10.7 million for the three month period ended June 30, 2026, compared with $9.7 million for the same period last year. The increase in operating expenses was driven by a $1.0 million increase selling, general and administrative expenses and a $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services.
Other expense, net was relatively flat at $1.1 million for each of the three months ended June 30, 2026 and 2025.
Net loss attributable to stockholders was $3.2 million, or $0.07 per share, for the three months ended June 30, 2026, compared with $3.8 million, or $0.09 per share, in the prior year period.
Adjusted EBITDA loss for the three months ended periods ended June 30, 2026 was $0.7 million as compared with an Adjusted EBITDA loss of $2.0 million for the three months ended June 30, 2025.
For the three months ended June 30, 2026, net cash used in operating activities was $3.5 million, compared with $1.2 million used in the three months ended June 30, 2025. The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss.
As of June 30, 2026, the Company had cash and cash equivalents of $27.6 million. Management believes based on its projections, including the uptake of the AYON platform, working capital management and its strict cost controls, the Company will yield cash through 2027.
Financial Guidance for Full Year 2026:
The Company reaffirmed its financial guidance targets for the year ending December 31, 2026:
- Total revenue in the range of $59.0 million to $60.0 million, compared with $52.8 million reported for the year ended December 31, 2025.
- Total revenue guidance assumes:
- Surgical Aesthetics revenue is expected to be in the range of $54.0 million to $55.0 million, compared with approximately $45.3 million reported for the year ended December 31, 2025.
- OEM revenue is expected to be approximately $5.0 million, compared with approximately $7.5 million for the year ended December 31, 2025.
- Total Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026.
Conference Call Details:
Management will host a conference call at 4:30 p.m. Eastern Time today, August 6th to discuss the results of the second quarter ended June 30, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and accessible directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1766208&tp_key=132ba2dca7
An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website.
About AYON Body Contouring System™:
AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring SystemTM in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents.
The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients.
The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements notice
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) (In thousands, except per share data)
| Three Months Ended | Six Months Ended |
|---|
| June 30, | June 30, |
|---|
| 2026 | 2025 | 2026 | 2025 |
|---|
| Sales, net | $13,884 | $11,373 | $26,374 | $20,803 |
| Cost of sales | 5,014 | 4,290 | 9,579 | 8,055 |
| Gross profit | 8,870 | 7,083 | 16,795 | 12,748 |
| Other costs and expenses: | | | | |
| Research and development | 793 | 824 | 1,558 | 1,628 |
| Professional services | 1,224 | 1,496 | 2,466 | 2,861 |
| Salaries and related costs | 3,374 | 3,072 | 6,627 | 6,153 |
| Selling, general and administrative | 5,285 | 4,265 | 8,861 | 7,731 |
| Total other costs and expenses | 10,676 | 9,657 | 19,512 | 18,373 |
| Loss from operations | (1,806) | (2,574) | (2,717) | (5,625) |
| Interest income | 250 | 278 | 494 | 582 |
| Interest expense | (1,394) | (1,393) | (2,763) | (2,769) |
| Other income, net | 2 | - | 38 | - |
| Total other expense, net | (1,142) | (1,115) | (2,231) | (2,187) |
| Loss before income taxes | (2,948) | (3,689) | (4,948) | (7,812) |
| Income tax expense | 124 | 49 | 267 | 98 |
| Net loss | (3,072) | (3,738) | (5,215) | (7,910) |
| Net loss attributable to non-controlling interest | 171 | 40 | 136 | 18 |
| Net loss attributable to stockholders | $(3,243) | $(3,778) | $(5,351) | $(7,928) |
| Loss per share: | | | | |
| Basic and diluted | $(0.07) | $(0.09) | $(0.12) | $(0.19) |
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| June 30, 2026 | |
|---|
| (Unaudited) | December 31, 2025 |
|---|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | $27,617 | $31,740 |
| Trade accounts receivable, net of allowance of $1,070 and $1,020 | 13,614 | 16,776 |
| Inventories, net of provision for obsolescence of $1,181 and $1,207 | 10,747 | 8,602 |
| Prepaid expenses and other current assets | 1,177 | 1,353 |
| Total current assets | 53,155 | 58,471 |
| Property and equipment, net of accumulated depreciation and amortization of $4,519 and $4,293 | 2,110 | 2,371 |
| Operating lease right-of-use assets | 4,014 | 4,218 |
| Finance lease right-of-use assets | 17 | 28 |
| Other assets | 1,776 | 1,752 |
| Total assets | $61,072 | $66,840 |
| LIABILITIES AND EQUITY | | |
| Current liabilities: | | |
| Accounts payable | $2,190 | $3,058 |
| Accrued expenses and other current liabilities | 6,692 | 8,214 |
| Current portion of operating lease liabilities | 451 | 407 |
| Current portion of finance lease liabilities | 21 | 21 |
| Total current liabilities | 9,354 | 11,700 |
| Long-term debt, net of debt discounts and issuance costs | 35,328 | 34,849 |
| Long-term operating lease liabilities | 3,828 | 4,051 |
| Long-term finance lease liabilities | 2 | 12 |
| Long-term contract liabilities | 1,134 | 1,050 |
| Other liabilities | 336 | 347 |
| Total liabilities | 49,982 | 52,009 |
| EQUITY | | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of June 30, 2026 and December 31, 2025 | - | - |
| Common stock, $0.001 par value; 75,000,000 shares authorized; 42,116,330 issued and outstanding as of June 30, 2026, and 41,785,946 issued and outstanding as of December 31, 2025 | 42 | 42 |
| Additional paid-in capital | 105,094 | 103,620 |
| Accumulated deficit | (94,473) | (89,122) |
| Total stockholders’ equity | 10,663 | 14,540 |
| Non-controlling interest | 427 | 291 |
| Total equity | 11,090 | 14,831 |
| Total liabilities and equity | $61,072 | $66,840 |
APYX MEDICAL CORPORATION
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
Use of Non-GAAP Financial Measure
The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.
| Three Months Ended | Six Months Ended |
|---|
| (In thousands) | June 30, | June 30, |
| 2026 | 2025 | 2026 | 2025 |
| Net loss attributable to stockholders | $(3,243) | $(3,778) | $(5,351) | $(7,928) |
| Interest income | (250) | (278) | (494) | (582) |
| Interest expense | 1,394 | 1,393 | 2,763 | 2,769 |
| Income tax expense | 124 | 49 | 267 | 98 |
| Depreciation and amortization | 196 | 132 | 398 | 270 |
| Stock-based compensation | 1,074 | 520 | 1,386 | 971 |
| Adjusted EBITDA | $(705) | $(1,962) | $(1,031) | $(4,402) |
Contacts
Jeremy Feffer, Managing Director, LifeSci Advisors
OP: 212-915-2568 jfeffer@lifesciadvisors.com